In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) were not associated with a significant increase in atrial fibrillation versus placebo or other non-GLP-1 RA drugs.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class, including liraglutide, were not linked to more atrial fibrillation than comparators.
- Peptide
- Liraglutide
- Outcome
- No significant changeAtrial fibrillation incidence
- Study
n: not reported in source
- Comparator
- Placebo or non-GLP-1 RA drugs
- Outcome group
- Cardiovascular events · Cardiovascular
Measurements
- Mantel-Haenszel OR
- 0.87 ratio
- pooled GLP-1 RA
Source sentences
In the remaining trials (enrolling 17,966 and 15,305 patients in GLP-1 RA and comparator arms, respectively, 55.3% women, with a mean age of 57.0 ± 3.8 years), treatment with GLP-1 RA was not associated with a significant increase in the incidence of atrial fibrillation [Mantel-Haenszel OR (95% CI)…
1 context sentence(design, population, supporting numbers)
A Medline search for GLP-1 RA (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥12 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 RA with placebo or any other non-GLP-1 RA drug.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.